Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640 demonstrates robust clinical efficacy and safety in a global phase 2 randomized placebo-controlled NASH trial (FASCINATE-1)
NASH-TAG
poster
Analysis of non-invasive biomarker tests in the Phase 2 FASCINATE-1 study of FASN inhibitor TVB-2640
EASL International Liver Congress
The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH
EASL International Liver Congress
FASN inhibition as a potential treatment for therapy of endocrine resistant breast cancer
San Antonio Breast Cancer Symposium
Updated results from a prospective, randomized phase 2 study in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with Avastin versus Avastin alone
Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN
Keystone Symposium on Organ Crosstalk in Obesity and NAFLD
